Literature DB >> 1845945

Ki-67 immunostaining in human breast tumors and its relationship to prognosis.

H O Wintzer1, I Zipfel, J Schulte-Mönting, U Hellerich, S von Kleist.   

Abstract

Ki-67 labeling was quantified in 37 nonmalignant breast tissues and in 63 breast carcinomas by counting ten random high-power fields each in three section planes (RC) or by evaluation of the area with the highest labeling density (HDC). Both procedures proved to be highly correlated (rs = 0.94). Ki-67-positive fractions of the nonmalignant tissues (mean, 2.1% for RC and 4.1% for HDC) were significantly lower as compared with the carcinomas (mean, 14.5% for RC and 17.5% for HDC). In carcinomas the Ki-67 labeling was significantly associated with pT stage, axillary lymph node status, and tumor grading and inversely related to progesterone receptor status. Using the medians of both counting methods (12% for RC and 17% for HDC) as cutoff points, significantly different curves for overall and disease-free survival (median follow-up, 37 months) were obtained. However, Cox multivariate analysis failed to demonstrate an independent effect of Ki-67 labeling. In contrast, Ki-67 reactivity seems to be of independent prognostic value if a higher cutoff level was selected.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1845945     DOI: 10.1002/1097-0142(19910115)67:2<421::aid-cncr2820670217>3.0.co;2-q

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  49 in total

Review 1.  Proliferation markers in tumours: interpretation and clinical value.

Authors:  P J van Diest; G Brugal; J P Baak
Journal:  J Clin Pathol       Date:  1998-10       Impact factor: 3.411

2.  Biological indices in the assessment of breast cancer.

Authors:  A S Leong; A K Lee
Journal:  Clin Mol Pathol       Date:  1995-10

3.  p63 and Ki-67 immunostainings in laryngeal squamous cell carcinoma are related to survival.

Authors:  M Re; A Zizzi; L Ferrante; D Stramazzotti; G Goteri; F M Gioacchini; F Olivieri; G Magliulo; C Rubini
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-01-09       Impact factor: 2.503

4.  Ki-67 immunostaining as a tool in the diagnosis of central cartilage lesions.

Authors:  L J Weinstein; E F McCarthy
Journal:  Iowa Orthop J       Date:  1996

5.  Prognostic value of proliferation markers expression in breast cancer.

Authors:  Natalija Dedić Plavetić; Jasminka Jakić-Razumović; Ana Kulić; Damir Vrbanec
Journal:  Med Oncol       Date:  2013-03-07       Impact factor: 3.064

6.  Ki-67 labelling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody.

Authors:  L Mastronardi; A Guiducci; C Spera; F Puzzilli; F Liberati; G Maira
Journal:  J Clin Pathol       Date:  1999-02       Impact factor: 3.411

7.  Correlation between conductivity and prognostic factors in invasive breast cancer using magnetic resonance electric properties tomography (MREPT).

Authors:  Soo-Yeon Kim; Jaewook Shin; Dong-Hyun Kim; Min Jung Kim; Eun-Kyung Kim; Hee Jung Moon; Jung Hyun Yoon
Journal:  Eur Radiol       Date:  2015-10-23       Impact factor: 5.315

8.  Prognostic value of ki-67 in breast carcinoma: tissue microarray method versus whole section analysis- potentials and pitfalls.

Authors:  Natalija Dedić Plavetić; Jasminka Jakić-Razumović; Ana Kulić; Maja Sirotković-Skerlev; Marina Barić; Damir Vrbanec
Journal:  Pathol Oncol Res       Date:  2014-08-06       Impact factor: 3.201

9.  Ki-67 and caspase expression in breast carcinoma: does variance in locational sampling exist?

Authors:  Filinte Deniz; Kaymakci Dilek; Mollamemisoglu Hande; Ugurlu M Umit; Kaya Handan
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

10.  Prognostic significance of a formalin-resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki-S1.

Authors:  H Kreipe; P Alm; H Olsson; M Hauberg; L Fischer; R Parwaresch
Journal:  Am J Pathol       Date:  1993-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.